SHC

+ Watchlist + Portfolio

Sotera Health Company

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $18.12
52-Week Range: $13.09 – $19.85
Market Cap: $5.20B
P/E (TTM): 31.96
EPS (TTM): 0.57
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 7.81
PEG Ratio: 1.31
Return on Equity: 27.78%
Return on Assets: 8.60%
Gross Margin: 54.97%
Operating Margin: 37.96%
Profit Margin: 13.44%
Current Ratio: 2.80
Debt/Equity: 3.41
Total Debt: $2.27B
Free Cash Flow: $153.97M
Revenue Growth: 9.20%
Earnings Growth: 569.50%
Enterprise Value: $7.11B

SHC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.00B	$1.05B	$1.10B	$1.16B
Cost of Revenue	$446.68M	$472.13M	$498.15M	$518.08M
Gross Profit	$557.00M	$577.16M	$602.29M	$645.53M
Selling, General & Admin	$245.71M	$236.67M	$242.63M	$252.76M
Operating Expenses	$308.65M	$300.47M	$304.67M	$283.50M
Operating Income	$248.35M	$276.69M	$297.63M	$362.03M
EBITDA	-$17.41M	$406.83M	$442.20M	$439.93M
Pretax Income	-$243.11M	$106.03M	$113.87M	$147.51M
Income Tax	-$9.54M	$54.65M	$69.48M	$69.56M
Net Income	-$233.57M	$51.38M	$44.40M	$77.95M
Diluted EPS	-0.83	0.18	0.16	0.27
Diluted Shares	280.10M	283.22M	284.91M	286.42M

SHC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$395.21M	$296.41M	$277.24M	$344.62M
Receivables	$155.72M	$175.52M	$165.81M	$176.27M
Inventory	$37.15M	$48.32M	$49.16M	$54.38M
Current Assets	$645.01M	$557.24M	$526.04M	$613.41M
Total Assets	$3.12B	$3.13B	$3.07B	$3.26B
Current Liabilities	$791.57M	$230.65M	$191.00M	$249.58M
Long-Term Debt	$1.75B	$2.22B	$2.21B	$2.13B
Total Debt	$2.03B	$2.33B	$2.35B	$2.27B
Total Liabilities	$2.77B	$2.69B	$2.67B	$2.66B
Retained Earnings	-$705.82M	-$654.44M	-$610.04M	-$532.09M
Shareholders' Equity	$350.24M	$443.73M	$404.91M	$606.03M
Working Capital	-$146.56M	$326.59M	$335.04M	$363.83M
Net Debt	$1.55B	$1.93B	$1.95B	$1.80B

SHC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$277.96M	-$147.73M	$224.16M	$287.19M
Capital Expenditure	-$182.38M	-$214.97M	-$179.07M	-$138.02M
Free Cash Flow	$95.58M	-$362.71M	$45.09M	$149.18M
Depreciation & Amortisation	$145.55M	$157.93M	$163.64M	$136.71M
Stock-Based Compensation	$21.21M	$32.24M	$36.78M	$30.88M
Investing Cash Flow	-$181.90M	-$214.91M	-$179.00M	-$135.14M
Financing Cash Flow	$197.76M	$265.96M	-$50.56M	-$100.53M
Share Repurchases	$0.00	-$4.09M	-$4.43M	—
Net Change in Cash	$293.83M	-$96.68M	-$5.40M	$51.52M

SHC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$254.52M	$294.34M	$311.31M	$303.44M	$280.05M	$321.38M
Cost of Revenue	$119.09M	$127.72M	$133.75M	$137.52M	$132.98M	$143.41M
Gross Profit	$135.43M	$166.62M	$177.56M	$165.92M	$147.07M	$177.96M
Selling, General & Admin	$63.06M	$68.89M	$63.29M	$57.51M	$68.21M	$68.16M
Operating Expenses	$78.39M	$78.19M	$66.38M	$60.54M	$71.24M	$71.17M
Operating Income	$57.04M	$88.43M	$111.18M	$105.38M	$75.83M	$106.79M
EBITDA	$66.86M	$94.56M	$140.44M	$138.07M	$108.17M	$145.85M
Pretax Income	-$14.82M	$18.90M	$72.94M	$70.50M	$42.61M	$78.05M
Income Tax	-$1.56M	$10.94M	$24.54M	$35.65M	$16.02M	$24.41M
Net Income	-$13.26M	$7.96M	$48.40M	$34.85M	$26.59M	$53.64M
Diluted EPS	-0.05	0.03	0.17	0.12	0.09	0.19
Diluted Shares	283.56M	285.76M	286.75M	287.55M	287.62M	288.15M

SHC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$304.39M	$332.44M	$299.19M	$344.62M	$314.15M	$356.72M
Receivables	$153.15M	$179.79M	$195.17M	$176.27M	$176.32M	$197.71M
Inventory	$61.05M	$59.95M	$49.87M	$54.38M	$57.49M	$56.37M
Current Assets	$554.99M	$608.17M	$577.82M	$613.41M	$585.97M	$646.46M
Total Assets	$3.10B	$3.22B	$3.19B	$3.26B	$3.24B	$3.31B
Current Liabilities	$225.99M	$246.32M	$242.40M	$249.58M	$207.80M	$231.24M
Long-Term Debt	$2.21B	$2.20B	$2.13B	$2.13B	$2.12B	$2.13B
Total Debt	$2.35B	$2.35B	$2.28B	$2.27B	$2.27B	$2.27B
Total Liabilities	$2.68B	$2.71B	$2.64B	$2.66B	$2.61B	$2.64B
Retained Earnings	-$623.30M	-$615.34M	-$566.94M	-$532.09M	-$505.50M	-$451.86M
Shareholders' Equity	$414.09M	$511.28M	$550.47M	$606.03M	$622.50M	$665.65M
Working Capital	$329.00M	$361.86M	$335.42M	$363.83M	$378.17M	$415.22M
Net Debt	$1.92B	$1.89B	$1.84B	$1.80B	$1.82B	$1.78B

SHC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$55.52M	$57.42M	$71.15M	$103.10M	$29.43M	$88.50M
Capital Expenditure	-$19.92M	-$31.23M	-$36.17M	-$50.70M	-$46.17M	-$46.45M
Free Cash Flow	$35.60M	$26.19M	$34.98M	$52.41M	-$16.73M	$42.05M
Depreciation & Amortisation	$40.80M	$35.02M	$28.36M	$32.53M	$30.81M	$33.40M
Stock-Based Compensation	$7.24M	$8.12M	$7.95M	$7.57M	$14.39M	$7.22M
Investing Cash Flow	-$19.88M	-$31.23M	-$33.34M	-$50.70M	-$45.13M	-$43.30M
Financing Cash Flow	-$8.09M	-$6.93M	-$77.34M	-$8.18M	-$12.78M	-$2.40M
Net Change in Cash	$27.55M	$19.25M	-$39.52M	$44.23M	-$28.47M	$42.79M

Market Snapshot

About

Sotera Health Company provides mission-critical sterilization and lab testing services for the healthcare industry. The company operates under three brands: Sterigenics for sterilization, Nordion for isotope technologies, and Nelson Labs for laboratory testing. Sotera Health serves medical device, pharmaceutical, and food safety customers globally.